Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma

Yeul Hong Kim, Seong Kyoon Cheong, Jee Dong Lee, Jeong Sik Park, Sang Won Shin, Jun Suk Kim

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

A phase II trial was performed with oral UFT plus leucovorin (LV) in 16 patients with advanced gastric carcinoma. Treatment consisted of UFT, 480 mg/m2/day, in conjunction with LV administered at 25 mg/m2/day per os in divided daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, with a median World Health Organization (WHO) performance status of 2. One patient was previously treated with etoposide, doxorubicin, and cisplatin (EAP). A median of four courses of treatment were given per patient (range: 1-9). Among 14 evaluable patients, one patient achieved a complete response and 3 had partial responses (response rate: 28.5%, 95% confidence interval, 4.9 to 52.3%). Stable disease was reported in 5 patients (35.7%) and another 5 showed progression. The time to progression was 17, 18, 27, and 76+ weeks for the responding patients, respectively. The median duration of survival was 25 weeks (range: 10-76+) for 14 evaluable patients. All patients were evaluable for toxicity. The main toxicity was diarrhea and oral mucositis. Significant toxicity (WHO grade 3 or 4) included diarrhea in 7 patients (43.8%), oral mucositis in 2 (12.5%), and nausea/vomiting in 2, respectively. We conclude that oral UFT plus LV, an out-patient regimen, has a favorable activity in gastric carcinoma patients and has tolerable toxicities.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number2
DOIs
Publication statusPublished - 1996 Apr 1

Fingerprint

Leucovorin
Stomach
Carcinoma
Stomatitis
Diarrhea
Etoposide
Doxorubicin
Nausea
Cisplatin
Vomiting
Outpatients
Confidence Intervals

Keywords

  • Advanced gastric carcinoma
  • Chemotherapy
  • Leucovorin
  • UFT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. / Kim, Yeul Hong; Cheong, Seong Kyoon; Lee, Jee Dong; Park, Jeong Sik; Shin, Sang Won; Kim, Jun Suk.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 2, 01.04.1996, p. 212-216.

Research output: Contribution to journalArticle

Kim, Yeul Hong ; Cheong, Seong Kyoon ; Lee, Jee Dong ; Park, Jeong Sik ; Shin, Sang Won ; Kim, Jun Suk. / Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1996 ; Vol. 19, No. 2. pp. 212-216.
@article{5246b64127f94cafa4e49cb9d5ffb6d6,
title = "Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma",
abstract = "A phase II trial was performed with oral UFT plus leucovorin (LV) in 16 patients with advanced gastric carcinoma. Treatment consisted of UFT, 480 mg/m2/day, in conjunction with LV administered at 25 mg/m2/day per os in divided daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, with a median World Health Organization (WHO) performance status of 2. One patient was previously treated with etoposide, doxorubicin, and cisplatin (EAP). A median of four courses of treatment were given per patient (range: 1-9). Among 14 evaluable patients, one patient achieved a complete response and 3 had partial responses (response rate: 28.5{\%}, 95{\%} confidence interval, 4.9 to 52.3{\%}). Stable disease was reported in 5 patients (35.7{\%}) and another 5 showed progression. The time to progression was 17, 18, 27, and 76+ weeks for the responding patients, respectively. The median duration of survival was 25 weeks (range: 10-76+) for 14 evaluable patients. All patients were evaluable for toxicity. The main toxicity was diarrhea and oral mucositis. Significant toxicity (WHO grade 3 or 4) included diarrhea in 7 patients (43.8{\%}), oral mucositis in 2 (12.5{\%}), and nausea/vomiting in 2, respectively. We conclude that oral UFT plus LV, an out-patient regimen, has a favorable activity in gastric carcinoma patients and has tolerable toxicities.",
keywords = "Advanced gastric carcinoma, Chemotherapy, Leucovorin, UFT",
author = "Kim, {Yeul Hong} and Cheong, {Seong Kyoon} and Lee, {Jee Dong} and Park, {Jeong Sik} and Shin, {Sang Won} and Kim, {Jun Suk}",
year = "1996",
month = "4",
day = "1",
doi = "10.1097/00000421-199604000-00026",
language = "English",
volume = "19",
pages = "212--216",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma

AU - Kim, Yeul Hong

AU - Cheong, Seong Kyoon

AU - Lee, Jee Dong

AU - Park, Jeong Sik

AU - Shin, Sang Won

AU - Kim, Jun Suk

PY - 1996/4/1

Y1 - 1996/4/1

N2 - A phase II trial was performed with oral UFT plus leucovorin (LV) in 16 patients with advanced gastric carcinoma. Treatment consisted of UFT, 480 mg/m2/day, in conjunction with LV administered at 25 mg/m2/day per os in divided daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, with a median World Health Organization (WHO) performance status of 2. One patient was previously treated with etoposide, doxorubicin, and cisplatin (EAP). A median of four courses of treatment were given per patient (range: 1-9). Among 14 evaluable patients, one patient achieved a complete response and 3 had partial responses (response rate: 28.5%, 95% confidence interval, 4.9 to 52.3%). Stable disease was reported in 5 patients (35.7%) and another 5 showed progression. The time to progression was 17, 18, 27, and 76+ weeks for the responding patients, respectively. The median duration of survival was 25 weeks (range: 10-76+) for 14 evaluable patients. All patients were evaluable for toxicity. The main toxicity was diarrhea and oral mucositis. Significant toxicity (WHO grade 3 or 4) included diarrhea in 7 patients (43.8%), oral mucositis in 2 (12.5%), and nausea/vomiting in 2, respectively. We conclude that oral UFT plus LV, an out-patient regimen, has a favorable activity in gastric carcinoma patients and has tolerable toxicities.

AB - A phase II trial was performed with oral UFT plus leucovorin (LV) in 16 patients with advanced gastric carcinoma. Treatment consisted of UFT, 480 mg/m2/day, in conjunction with LV administered at 25 mg/m2/day per os in divided daily doses for 21 days followed by a 7-day rest period. The median age of the patients was 64 years, with a median World Health Organization (WHO) performance status of 2. One patient was previously treated with etoposide, doxorubicin, and cisplatin (EAP). A median of four courses of treatment were given per patient (range: 1-9). Among 14 evaluable patients, one patient achieved a complete response and 3 had partial responses (response rate: 28.5%, 95% confidence interval, 4.9 to 52.3%). Stable disease was reported in 5 patients (35.7%) and another 5 showed progression. The time to progression was 17, 18, 27, and 76+ weeks for the responding patients, respectively. The median duration of survival was 25 weeks (range: 10-76+) for 14 evaluable patients. All patients were evaluable for toxicity. The main toxicity was diarrhea and oral mucositis. Significant toxicity (WHO grade 3 or 4) included diarrhea in 7 patients (43.8%), oral mucositis in 2 (12.5%), and nausea/vomiting in 2, respectively. We conclude that oral UFT plus LV, an out-patient regimen, has a favorable activity in gastric carcinoma patients and has tolerable toxicities.

KW - Advanced gastric carcinoma

KW - Chemotherapy

KW - Leucovorin

KW - UFT

UR - http://www.scopus.com/inward/record.url?scp=0344655446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344655446&partnerID=8YFLogxK

U2 - 10.1097/00000421-199604000-00026

DO - 10.1097/00000421-199604000-00026

M3 - Article

VL - 19

SP - 212

EP - 216

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -